Therapeutic approaches directed toward a single pathway or single target such as AR antagonism or prostate-specific membrane antigen radioligand therapy may potently inhibit specific disease subtypes but are unlikely to overcome the heterogeneity commonly seen in advanced prostate cancer (49). Here, FOLH1 is linked to prostate cancer.